Pharmaceutical Management
Pharmaceutical Management in NIPER JEE tests Indian drug regulation, pricing, patents, GMP, pharmacoeconomics, marketing, and supply-chain decisions.
Core rules and concepts
- DPCO 2013 places scheduled formulations under NPPA ceiling prices; ceiling price is calculated from market data and applies to all brands, while MRP must not exceed it.
- Patents in India run 20 years from filing; trademarks protect brand names indefinitely if renewed. TRIPS requires product and process patents, but compulsory licensing is possible.
- Schedule M is India’s GMP requirement; WHO GMP and ICH Q7 apply to active pharmaceutical ingredients. CDSCO is the national regulator.
- Pharmacoeconomics compares costs and outcomes: cost-effectiveness uses ICER = ΔCost/ΔEffect; a QALY combines quality and length of life.
- Product life cycle: introduction, growth, maturity, decline; patent expiry invites generic entry and price erosion.
Worked example
A new therapy costs ₹80,000 and gives 0.85 QALY; standard therapy costs ₹50,000 and gives 0.70 QALY. ΔCost = ₹30,000; ΔEffect = 0.15 QALY. ICER = 30,000/0.15 = ₹200,000 per QALY. If the willingness-to-pay threshold is ₹250,000/QALY, the new therapy is cost-effective from the health-system perspective.
Traps that cost marks
- Counting patent life from grant date rather than filing date.
- Confusing DPCO ceiling price with ordinary MRP.
- Mixing perspectives: patient out-of-pocket costs differ from payer costs.
- Treating a trademark as a patent; trademarks do not protect the molecule.